miR-325-3p Facilitates Tumorigenesis and Acquired Pemigatinib Resistance in Intrahepatic Cholangiocarcinoma via Targeting ADH1B through Epithelial–Mesenchymal Transition and PI3K/AKT Signaling

Inside the human body, the liver performs a vast array of chemical tasks, but it is also the site where a particularly aggressive form of cancer can take root. This disease, known as intrahepatic cholangiocarcinoma, begins in the bile ducts that run through the liver. It is a formidable adversary; once diagnosed, the outlook is often grim, with very few patients surviving five years. For those whose cancer carries a specific genetic change called an FGFR2 rearrangement, doctors have a targeted weapon: a drug called pemigatinib. This medication acts like a precise lockpick, disabling the faulty switch that drives the cancer cells to multiply. However, like many treatments, it faces a stubborn problem. Over time, the cancer often learns to ignore the drug, finding a way to keep growing despite the presence of the medicine. The reason for this resistance has remained a mystery, leaving doctors without a clear path forward for patients who stop responding to therapy.

To solve this puzzle, a team of researchers set out to look deeper into the molecular machinery of these cancer cells. They were interested in a tiny piece of genetic material called a microRNA, specifically one named miR-325-3p. Think of these microRNAs as small managers that tell other genes when to work and when to rest. In healthy cells, these managers keep things balanced, but in cancer, they can go rogue, turning off the genes that are supposed to stop the tumor from growing. The researchers suspected that miR-325-3p might be one of these rogue managers in intrahepatic cholangiocarcinoma, and they wanted to see what gene it was silencing and how that silence led to drug resistance.

The investigation began by comparing the genetic profiles of cancer tissue from patients with healthy tissue. The researchers found that a gene called ADH1B was significantly quieter in the cancer cells than in the healthy ones. ADH1B is an enzyme that normally helps the body process alcohol and certain vitamins, but in this context, it acts as a tumor suppressor—a brake on cancer growth. When the researchers artificially boosted the levels of ADH1B in cancer cells in the lab, the cells stopped multiplying as quickly and began to die off naturally. They also found that these cells became less able to spread and invade other tissues. This confirmed that the loss of ADH1B was a key factor in making the cancer aggressive.

Next, the team looked for the manager responsible for silencing this brake. They discovered that miR-325-3p was present in much higher amounts in the cancer cells. Through a series of experiments, they proved that miR-325-3p directly binds to the instructions for ADH1B, effectively blocking the cell from making the enzyme. It was a direct cause-and-effect relationship: high levels of miR-325-3p meant low levels of ADH1B, which in turn meant the cancer cells were free to grow and spread. The researchers observed that when miR-325-3p was active, it triggered a chain reaction inside the cell. It turned on a powerful signaling pathway known as PI3K/AKT, which acts like a master switch for cell growth and survival. This activation also caused the cells to change their shape and behavior, becoming more mobile and invasive, a process known as the epithelial-mesenchymal transition.

The most critical part of the study involved testing how this mechanism affected the drug pemigatinib. The researchers treated cancer cells with the drug and watched what happened. In cells where miR-325-3p was high and ADH1B was low, the cancer cells ignored the drug and continued to thrive. However, when the researchers forced the cells to make more ADH1B again, the cancer cells suddenly became sensitive to pemigatinib once more. They also found that if they blocked the PI3K/AKT signaling pathway with another drug, the cancer cells lost their resistance and responded to pemigatinib again. This suggested that the cancer was not becoming resistant through a new mutation in the drug's target, but rather by using a different, parallel route to keep growing. The miR-325-3p manager was essentially rerouting the cell's energy away from the drug's target and toward a survival path that the drug could not stop.

To see if these findings held true in a living system, the researchers grew tumors in mice. They created two groups of mice: one with tumors that had low levels of ADH1B and one with normal levels. The tumors with low ADH1B grew much faster and were larger than the others. When the researchers examined these tumors, they found the same signs of aggressive behavior and active signaling pathways seen in the lab dishes. This confirmed that the mechanism was not just a laboratory artifact but a real driver of disease progression.

The study concludes that the relationship between miR-325-3p and ADH1B is a major factor in how this cancer develops and how it resists treatment. By silencing the ADH1B brake, the cancer cells activate a survival pathway that allows them to bypass the effects of pemigatinib. This discovery offers a new way to look at the disease. It suggests that in the future, doctors might be able to test patients for the levels of miR-325-3p to predict who will develop resistance. Furthermore, it points to a potential new strategy for treatment: combining the current drug with therapies that either block miR-325-3p or reactivate ADH1B, or simply block the PI3K/AKT pathway that the cancer uses to survive. While these ideas are still in the early stages and require further testing, the research provides a clear map of a hidden mechanism that has long kept this cancer one step ahead of treatment.